Elevations in cancer treatment-induced circulating inflammatory cytokines may be partially responsible for the development of significant symptom burden (e.g., pain, fatigue, distress, disturbed sleep) during concurrent chemoradiation therapy (CXRT). Sixty-two patients undergoing CXRT for locally advanced non-small cell lung cancer (NSCLC) reported symptoms weekly for 15 weeks via the M. D. Anderson Symptom Inventory (MDASI). Serum inflammatory cytokines were assessed weekly during therapy via enzyme-linked immunosorbent assay. Dynamic changes in cytokines and associated symptom profiles were estimated using mixed-effect models. MDASI symptom severity increased gradually as CXRT dose accumulated and peaked at week 8. Serum concentrations of interleukin (IL)-6, IL-10, and serum soluble receptor 1 for tumor necrosis factor (sTNF-R1) increased significantly by week 8 (all p < .05). During CXRT, controlled for age, sex, race, body mass index, cancer recurrence, previous treatment status, total radiotherapy dose, and CXRT delivery technique, an increase in sTNF-R1 was significantly related to an increase in the mean score for all 15 MDASI symptoms (estimate, 1.74; SE, 0.69; p < .05) and to a larger radiation dose to normal lung volume (estimate, 1.77; SE, 0.71; p < .01); an increase in serum IL-6 was significantly related to increased mean severity for the five most severe symptoms (pain, fatigue, disturbed sleep, lack of appetite, sore throat) (estimate, 0.32; SE, 0.16; p < .05). These results suggest a role for over-expressed pro-inflammatory cytokines in significant worsening of symptoms in NSCLC patients undergoing CXRT, and warrant further study to identify biological targets for ameliorating treatmentrelated symptom burden.
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Introduction
Lung cancer is a highly symptomatic disease that has the secondhighest yearly incidence rate among all cancers in the United States (Jemal et al., 2009) . Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. The treatment of choice for loco-regional and advanced NSCLC is concurrent chemoradiation therapy (CXRT) (Jemal et al., 2009; Yamamoto et al., 2006) , a modality that is frequently associated with multiple symptoms induced by accumulating doses of radiation and chemotherapy (Wang et al., 2006) . However, with the exception of pain, many non-specific cancer symptoms-such as fatigue, disturbed sleep, poor appetite, and distress-are not intentionally monitored in the clinical setting and may not be treated as specific toxicities of cancer or cancer treatment (Cleeland, 2000; Cox et al., 1995; Patrick et al., 2004) . Collectively, these non-specific symptoms and toxicities form a ''symptom burden" that can affect patient functioning. Symptom burden may provoke treatment interruptions, such as dose reduction or withdrawal from chemotherapy and/or radiotherapy for patients with NSCLC, which could compromise the effectiveness of intervention (Cleeland, 2007) .
Controlling symptoms requires first that they be assessed, preferably throughout the course of treatment. The subjective nature of the symptom experience has necessitated the use of validated multiple-symptom assessment instruments that can capture the patient's own report of the severity of symptoms (so-called patient-reported outcomes).
Controlling symptoms also requires a better understanding of the mechanism(s) underlying the development of treatment-related symptoms. Recent cancer research has shown that symptoms such as pain, fatigue, and disturbed sleep frequently cluster together and often share the same developmental pattern over the trajectory of disease progression and treatment (Barsevick et al., 
